Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Trading DecisionBuy
Generated at:2026-03-04 16:40:52
Analysis based on comprehensive technical indicators, fundamental data, market sentiment, and analyst perspectives. Data includes current price as of 2026-03-04, historical financial metrics, technical indicators (RSI, Bollinger Bands, moving averages), and forward-looking pipeline information through 2026.
Summary

Pfizer, Inc. (PFE) presents a compelling BUY opportunity with current price at $26.62. Target price is set at $29.00 (9% upside), with stop-loss at $25.40. Confidence level is 0.72 and risk score is 0.65 (moderate-high risk). The recommendation is based on attractive valuation, oversold technical conditions, strong dividend yield, and positive oncology catalysts.

Operation strategy
  • Target price: $29.00 (9% upside from current price)
  • 1-Month Target Range: $27.50-$28.00 (3-5% upside)
  • 3-Month Target Range: $29.00-$30.00 (9-13% upside)
  • 6-Month Target Range: $31.00-$32.00 (16-20% upside)
  • Stop-Loss: $25.40 (4.6% below current price)
  • Position Size: Moderate allocation due to 50% historical stop-loss trigger rate
  • Time Horizon: 3-6 months for target achievement

Core Support

Reasoning summary
  • Attractive Valuation: P/E ratio of 19.45 is below industry average (~20-25), suggesting undervaluation
  • Strong Profitability: 74.33% gross margins demonstrate pricing power and operational efficiency
  • Dividend Support: 6.3% yield with 14-year consecutive increase history provides downside protection
  • Core Business Growth: Ex-COVID revenue grew 5% in 2025, indicating healthy underlying business
  • Robust Pipeline: Over 20 Phase 3 readouts expected through 2026, including recent oncology breakthroughs
  • Oversold Conditions: RSI_6 at 37.04 approaching oversold territory
  • Support Proximity: Trading near Bollinger Lower Band ($26.38) and MA_60 ($26.09) support
  • Historical Support: Strong chip concentration around $26.26-$27.51 provides technical foundation
  • Positive Catalyst: Recent oncology news (PADCEV+Keytruda results) provides 3-6% upside potential
  • Patent Cliff Concerns: Major Eliquis patent expiry not until late 2026/2027, providing transition time